SI1767535T1 - Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh - Google Patents

Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh

Info

Publication number
SI1767535T1
SI1767535T1 SI200331750T SI200331750T SI1767535T1 SI 1767535 T1 SI1767535 T1 SI 1767535T1 SI 200331750 T SI200331750 T SI 200331750T SI 200331750 T SI200331750 T SI 200331750T SI 1767535 T1 SI1767535 T1 SI 1767535T1
Authority
SI
Slovenia
Prior art keywords
epothilones
analogues
intermediates
synthesis
formula
Prior art date
Application number
SI200331750T
Other languages
English (en)
Slovenian (sl)
Inventor
Samuel J Danishefsky
Alexey Rivkin
Fumihiko Yoshimura
Ortega Ana Esther Gabarda
Young Shin Cho
Ting-Chao Chou
Huajin Dong
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/402,004 external-priority patent/US6921769B2/en
Priority claimed from US10/435,408 external-priority patent/US7649006B2/en
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of SI1767535T1 publication Critical patent/SI1767535T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI200331750T 2002-08-23 2003-08-22 Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh SI1767535T1 (sl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US40582302P 2002-08-23 2002-08-23
US40858902P 2002-09-06 2002-09-06
US42312902P 2002-11-01 2002-11-01
US45615903P 2003-03-20 2003-03-20
US10/402,004 US6921769B2 (en) 2002-08-23 2003-03-28 Synthesis of epothilones, intermediates thereto and analogues thereof
US10/435,408 US7649006B2 (en) 2002-08-23 2003-05-09 Synthesis of epothilones, intermediates thereto and analogues thereof
US49674103P 2003-08-21 2003-08-21
EP06026750A EP1767535B1 (en) 2002-08-23 2003-08-22 Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Publications (1)

Publication Number Publication Date
SI1767535T1 true SI1767535T1 (sl) 2010-03-31

Family

ID=31950966

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331750T SI1767535T1 (sl) 2002-08-23 2003-08-22 Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh

Country Status (18)

Country Link
US (1) US7875638B2 (enExample)
EP (3) EP2186811A1 (enExample)
JP (2) JP4791183B2 (enExample)
KR (1) KR101173510B1 (enExample)
CN (2) CN102532120A (enExample)
AT (2) ATE350383T1 (enExample)
AU (1) AU2003260002B2 (enExample)
CA (1) CA2496477C (enExample)
DE (2) DE60330407D1 (enExample)
DK (2) DK1506203T3 (enExample)
ES (2) ES2281692T3 (enExample)
IL (1) IL167046A (enExample)
MX (1) MXPA05002113A (enExample)
NZ (1) NZ538522A (enExample)
PH (1) PH12012501351A1 (enExample)
PT (2) PT1506203E (enExample)
SI (1) SI1767535T1 (enExample)
WO (1) WO2004018478A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP2186811A1 (en) * 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
AU2003264822A1 (en) * 2002-10-11 2004-05-04 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
EP2135867B1 (en) * 2002-11-07 2013-09-25 Kosan Biosciences Incorporated Trans-9, 10-dehydroepothilone C and trans-9, 10-dehydroepothilone D, analogs thereof and methods of making the same
KR20060122819A (ko) * 2003-10-09 2006-11-30 코산 바이오사이언시즈, 인코포레이티드 치료학적 제형
AU2005299385B2 (en) 2004-10-25 2011-06-16 Dekk-Tec Inc. Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
US7238816B2 (en) * 2005-04-21 2007-07-03 Hoffmann-La Roche Inc. Preparation of epothilone derivatives
US20120128657A1 (en) 2007-02-07 2012-05-24 Bewley Carole A Synthetic macrocyclic compounds and methods for treating cancer
PT2581367E (pt) 2007-04-06 2016-03-28 Ziopharm Oncology Inc Sais de mostarda de isofosforamida e seus análogos
WO2008141234A2 (en) * 2007-05-11 2008-11-20 Kosan Biosciences Incorporated Methods of making epothilones
WO2009112077A1 (en) * 2008-03-13 2009-09-17 F. Hoffmann-La Roche Ag Process for the preparation of epothilone precursor compounds
MX2011001122A (es) 2008-07-31 2011-03-29 Ziopharm Oncology Inc Sintesis y formulaciones de sales de mostaza de isofosforoamida y analogos de las mismas.
EP2401285B1 (en) 2009-02-24 2012-10-10 Dekk-Tec, Inc. Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents
WO2010138686A1 (en) 2009-05-29 2010-12-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mdri-inverse agents
CN101747326B (zh) * 2010-01-12 2012-07-25 山东大学 18元大环内酯类埃博霉素化合物及其应用
JP5837890B2 (ja) 2010-03-10 2015-12-24 アメリカ合衆国 神経膠芽腫および星状細胞腫の治療におけるフェノテロールおよびフェノテロール類似体の使用
WO2012033601A1 (en) 2010-08-20 2012-03-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Thiosemicarbazones with mdr1 - inverse activity
EP2731626B1 (en) 2011-07-11 2018-12-19 THE UNITED STATES OF AMERICA, represented by the S Photosensitizing antibody-fluorophore conjugates
EP2854855B1 (en) 2012-05-25 2016-04-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
ES2764833T3 (es) 2013-10-11 2020-06-04 The United States Of America Represented By The Sec Dep Of Health And Human Services Anticuerpos contra TEM8 y su uso
US10830678B2 (en) 2014-08-08 2020-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Photo-controlled removal of targets in vitro and in vivo
PE20180796A1 (es) 2015-10-27 2018-05-09 Hoffmann La Roche Macrociclos peptidicos contra acinetobacter baumannii
CA3081436A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
WO2019099615A1 (en) 2017-11-17 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US20210079112A1 (en) 2018-04-10 2021-03-18 The United States of America, as represented by the Secretary, Department of Health and Human Ser Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
EP3994173A1 (en) 2019-07-02 2022-05-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind egfrviii and their use
US12503695B2 (en) 2020-01-27 2025-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RAB13 and NET1 antisense oligonucleotides to treat metastatic cancer
AU2021385059A1 (en) 2020-11-19 2023-06-08 Kalivir Immunotherapeutics, Inc. Oncolytic immunotherapy by tumor micro-environment remodeling
AU2022213415A1 (en) 2021-01-29 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Near infrared photoimmunotherapy (nir-pit) combination therapy to treat cancer
IL316712B2 (en) 2021-04-30 2025-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for modified mhc expression
CN116710085A (zh) * 2021-12-31 2023-09-05 成都华昊中天药业有限公司 优替德隆脂质体组合物及其制备方法和用途
CN119816324A (zh) 2022-06-30 2025-04-11 美国政府(由卫生和人类服务部的部长所代表) Cd25特异性抗体及其用途
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605661A (en) * 1984-06-18 1986-08-12 Eli Lilly And Company Aromastase inhibiting α,α-diarylimidazole-4(5)-propionitriles, α,α-diarylimidazole-4(5)-propionamides, and 4(5)-(2,2-diarylethyl)imidazoles
EP0225292A3 (en) 1985-12-06 1988-11-30 Ciba-Geigy Ag Certain n-substituted butyramide derivatives
DE3811574A1 (de) * 1988-03-31 1989-10-19 Schering Ag N-substituierte imidazole, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
EP1652539B8 (en) 1993-07-19 2011-06-15 Angiotech Pharmaceuticals, Inc. Method of manufacturing a stent comprising an anti-angiogenic composition
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
DE19607702A1 (de) 1996-02-29 1997-09-04 Biotechnolog Forschung Gmbh Heterozyklische Verbindungen, Herstellungsverfahren und Mittel
EP0932399B1 (en) 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US20040106985A1 (en) 1996-04-26 2004-06-03 Jang G. David Intravascular stent
US5917084A (en) 1996-07-03 1999-06-29 Millennium Pharmaceuticals, Inc. Antifungal agents
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
DE19638870B4 (de) 1996-09-23 2009-05-14 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysine, Verfahren zu ihrer Gewinnung und sie enthaltende Mittel
DK1367057T3 (da) * 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
AU736062B2 (en) 1997-02-25 2001-07-26 Gesellschaft Fur Biotechnologische Forschung Mbh Epothilones which are modified in the side chain
US20020086812A1 (en) 1997-03-04 2002-07-04 Schweinfest Clifford W. Methods and compositions for diagnosis and treatment of cancer
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja) 1997-04-18 2008-03-26 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19849464A1 (de) 1997-04-30 2000-04-27 Schering Ag Wirkstofffreisetzende Stents, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe
US6117659A (en) 1997-04-30 2000-09-12 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
US20030049841A1 (en) 1997-06-16 2003-03-13 Short Jay M. High throughput or capillary-based screening for a bioactivity or biomolecule
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DK1001951T3 (da) 1997-07-16 2002-12-23 Schering Ag Thiazolderivater, fremgangsmåde til fremstilling deraf og anvendelse af disse
DE19813821A1 (de) 1998-03-20 1999-09-23 Schering Ag Verfahren zur Herstellung von C1-C6-Bausteinen zur Totalsynthese von Epothilon und Epothilon-Derivaten
DE19735574A1 (de) 1997-08-09 1999-02-11 Schering Ag Neue [C1(Carboxa)-C6]-Fragmente, Verfahren zu ihrer Herstellung und ihre Verwendung zur Synthese von Epothilon und Epothilonderivaten
CA2299608A1 (en) 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
DE19749717A1 (de) 1997-10-31 1999-05-06 Schering Ag Neue C1-C6-Bausteine zur Totalsynthese neuer Epothilon-Derivate sowie Verfahren zur Herstellung dieser Bausteine
DE19735575A1 (de) 1997-08-09 1999-02-11 Schering Ag Neue (C13-C15)-Fragmente, Verfahren zur Herstellung und ihre Verwendung zur Synthese von Epothilon und Epothilonderivaten
DE19735578A1 (de) 1997-08-09 1999-02-11 Schering Ag Neue (C1-C6)-Fragmente, Verfahren zur Herstellung und ihre Verwendung zur Synthese von Epothilon und Epothilonderivaten
DE19751200A1 (de) 1997-11-13 1999-05-20 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19744135C1 (de) 1997-09-29 1999-03-25 Schering Ag Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6280999B1 (en) 1998-01-23 2001-08-28 Kosan Bioscience Sorangium polyketide synthases and encoding DNA therefor
US6090601A (en) 1998-01-23 2000-07-18 Kosan Bioscience Sorangium polyketide synthase
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
PT1052974E (pt) 1998-02-05 2009-08-07 Novartis Ag Formulação farmacêutica contendo epotilona
DE19804673A1 (de) 1998-02-06 1999-08-12 Studiengesellschaft Kohle Mbh Verfahren zur Darstellung makrocyclischer Produkte durch ringschliessende Diin-Metathese
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6302838B1 (en) 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
US6407103B2 (en) 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
JPH11322611A (ja) * 1998-05-14 1999-11-24 Sankyo Co Ltd 抗ウイルス剤
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
DE19826988A1 (de) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
DE19923001A1 (de) 1999-05-13 2000-11-16 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung, Zwischenprodukte und ihre pharmazeutische Verwendung
DE19830060A1 (de) 1998-06-30 2000-02-10 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung, Zwischenprodukte und ihre pharmazeutische Verwendung
US6221641B1 (en) 1998-07-02 2001-04-24 Leland Stanford Junior University Method for making polyketides
US20030199535A1 (en) 1998-07-30 2003-10-23 Claudio Cavazza Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
ATE346938T1 (de) 1998-10-02 2006-12-15 Kosan Biosciences Inc Polyketid synthase enzyme und rekombinante dna konstrukte dafür, zur herstellung von mit fk-506 und fk-520 verwandten verbindungen
DE19846493A1 (de) 1998-10-09 2000-04-13 Biotechnolog Forschung Gmbh DNA-Sequenzen für die enzymatische Synthese von Polyketid- oder Heteropolyketidverbindungen
DE19848306A1 (de) 1998-10-14 2000-04-20 Schering Ag Verfahren zur Herstellung von Epothilon B und Derivaten sowie Zwischenprodukte für dieses Verfahren
WO2000026349A2 (en) 1998-10-29 2000-05-11 Kosan Biosciences, Inc. Recombinant oleandolide polyketide synthase
US6303767B1 (en) 1998-11-05 2001-10-16 Kosan Biosciences, Inc. Nucleic acids encoding narbonolide polyketide synthase enzymes from streptomyces narbonensis
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
AU2795000A (en) 1998-12-22 2000-07-12 Novartis Ag Epothilone derivatives and their use as antitumor agents
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
DE19908763A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19908765A1 (de) 1999-02-18 2000-08-24 Schering Ag 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19954230A1 (de) 1999-11-04 2001-11-15 Schering Ag 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19908760A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19908767A1 (de) 1999-02-18 2000-10-19 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US6406722B1 (en) 1999-02-18 2002-06-18 Robert G. Gallaher Method of treating viral infections and lesions with taxane compounds
CN1209360C (zh) 1999-02-18 2005-07-06 舍林股份公司 16－卤－依泊昔酮衍生物、其制备方法及其医药用途
WO2000048606A1 (en) 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
TR200102401T2 (tr) 1999-02-22 2001-12-21 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 Değiştirilmiş epotilonlar.
DE19930111A1 (de) 1999-07-01 2001-01-04 Biotechnolog Forschung Gmbh C-21 Modifizierte Epothilone
DE19907588A1 (de) 1999-02-22 2000-08-24 Biotechnolog Forschung Gmbh C-21 Modifizierte Epothilone
US20020058286A1 (en) 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
US6603015B2 (en) 1999-03-29 2003-08-05 University Of Kansas Synthesis of epothilones
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
ATE275177T1 (de) 1999-04-06 2004-09-15 Seiko Epson Corp Tintenzusammensetzung enthaltend einen kupferkomplex-farbstoff
CA2369303A1 (en) 1999-04-14 2000-10-19 Arthur B. Pardee Method and composition for the treatment of cancer
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
PT1169038E (pt) 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
DE19954228A1 (de) 1999-11-04 2001-09-13 Schering Ag 6-Alkenyl-und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
DE10015836A1 (de) 2000-03-27 2001-10-11 Schering Ag 6-Alkenyl- und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
JP4707240B2 (ja) * 1999-05-05 2011-06-22 アベンティス・フアーマ・リミテッド 細胞接着調節剤としての尿素
KR100621185B1 (ko) 1999-09-09 2006-09-06 삼성전자주식회사 디디씨 모니터의 동작 기록형 마이크로컴퓨터의 제어방법
US6569867B2 (en) 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives
US20020147197A1 (en) 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
US20030054977A1 (en) 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US20020045220A1 (en) 1999-10-13 2002-04-18 Chaitan Khosla Biosynthesis of polyketide synthase substrates
CN1086389C (zh) * 1999-11-12 2002-06-19 中国科学院上海有机化学研究所 异埃坡霉素及合成方法
US20030036177A1 (en) 2002-08-13 2003-02-20 Joachim Strohhacker Single colonies of myxobacteria cells
EP1259490A2 (en) 2000-03-01 2002-11-27 Sloan Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
DE10020517A1 (de) 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE10020899A1 (de) 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
US6998256B2 (en) 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
US6489314B1 (en) 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
EP1278882A4 (en) 2000-05-02 2004-08-18 Kosan Biosciences Inc OVER PRODUCTION INNOVERS FOR THE BIOSYNTHESIS OF POLYKETIDES
AU2001266583A1 (en) 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP1303615A2 (en) 2000-07-25 2003-04-23 Kosan Biosciences, Inc. Fermentation process for epothilones
JP2004520008A (ja) 2000-08-09 2004-07-08 コーサン バイオサイエンシーズ， インコーポレイテッド ポリケチドの化学合成において使用するための生物中間体
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
JP2004517045A (ja) * 2000-08-18 2004-06-10 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 癌およびｈｉｖの治療用ベツリン酸誘導体のプロドラッグ
US7766956B2 (en) 2000-09-22 2010-08-03 Boston Scientific Scimed, Inc. Intravascular stent and assembly
AU2002213248A1 (en) 2000-10-13 2002-04-22 The University Of Mississipi Synthesis of epothilones and relates analogs
DE10051136A1 (de) 2000-10-16 2002-04-18 Ludger A Wessjohann Epothilone-Synthesebausteine III und Verfahren zur Herstellung von Epothilon B, D und Epothilonderivaten
EP1358144B1 (de) 2000-10-16 2006-12-27 R&D-Biopharmaceuticals Epothilon-synthesebausteine i: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie deren verwendung zur herstellung von epothilonen und epothilonderivaten
WO2002058694A2 (en) 2000-11-07 2002-08-01 Dana-Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers using beta lapachone
US7070797B2 (en) 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
EP1363996A2 (en) 2000-11-22 2003-11-26 Novartis AG Epothilone resistant cell lines
GB0029895D0 (en) 2000-12-07 2001-01-24 Novartis Ag Organic compounds
EP1353667A1 (en) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
ES2304240T3 (es) 2001-01-25 2008-10-01 Bristol-Myers Squibb Company Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
US20030004338A1 (en) 2001-02-01 2003-01-02 Li Wen Sen Process for the preparation of epothilone analogs
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP1368030A1 (en) 2001-02-20 2003-12-10 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
BR0207487A (pt) 2001-02-20 2004-08-10 Brystol Myers Squibb Company Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
DE60213884T2 (de) 2001-02-27 2007-02-22 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Verfahren zur Herstellung von Epothilonen
WO2002067941A2 (en) 2001-02-27 2002-09-06 Novartis Ag Combination comprising a signal transduction inhibitor and an epothilone derivative
ES2384789T3 (es) 2001-03-14 2012-07-12 Bristol-Myers Squibb Company Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas
US7030147B2 (en) 2001-03-19 2006-04-18 Novartis Ag Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
PE20020908A1 (es) 2001-03-21 2002-10-26 Cell Therapeutics Inc Produccion recombinante de polimeros polianionicos y uso de de los mismos
EP1383492A4 (en) 2001-03-23 2008-12-24 Napro Biotherapeutics Inc MOLECULAR CONJUGATES FOR USE IN CANCER THERAPY
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
EP1610751A4 (en) 2001-04-26 2006-05-24 Univ Texas THERAPEUTIC AGENT / LIGAND CONJUGATE COMPOSITIONS, ITS SYNTHESIS PROCESSES AND ITS APPLICATION
US6906188B2 (en) 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
US20030023082A1 (en) 2001-05-15 2003-01-30 Gary Ashley Epothilone derivatives and methods for making and using the same
JP2004532888A (ja) 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
JP4779298B2 (ja) 2001-06-25 2011-09-28 味の素株式会社 抗腫瘍剤
DE10138347A1 (de) 2001-08-03 2003-02-27 Schering Ag Geschützte 3,5-Dihydroxy-2,2-dimethyl-valeronitrile für die Synthese von Epothilonen- und Derivaten und Verfahren zur Herstellung
US6933385B2 (en) 2001-08-03 2005-08-23 Schering Ag Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for the production and the use
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1420780B1 (en) 2001-08-23 2008-10-01 Novartis AG Cyclopropyl and cyclobutyl epothilone analogs
JP2005504065A (ja) 2001-08-31 2005-02-10 ブリストル−マイヤーズ　スクイブ　カンパニー 癌治療のための組成物および方法
US6903102B2 (en) 2001-09-06 2005-06-07 Schering Corporation 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2003022844A2 (en) * 2001-09-06 2003-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones intermediates thereto and analogues thereof
WO2003029195A1 (en) 2001-09-28 2003-04-10 Sumika Fine Chemicals Co., Ltd. Intermediates for epothilone derivative and process for producing these
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
US20030134883A1 (en) 2001-11-26 2003-07-17 David Myles 14-Methyl-epothilones
AU2002346644A1 (en) 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
DE10164592A1 (de) 2001-12-21 2003-07-03 Schering Ag C1-C6-Epothilon-Fragmente und Verfahren für die Herstellung von C1-C6-Fragmenten von Epothilonen und deren Derivaten
US6884608B2 (en) 2001-12-26 2005-04-26 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
US6900331B2 (en) 2002-03-01 2005-05-31 University Of Notre Dame Derivatives of epothilone B and D and synthesis thereof
EP1340498A1 (en) 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
MXPA04008630A (es) 2002-03-07 2004-12-06 Univ Illinois Compuestos estabilizantes microtubulares.
DE60330651D1 (en) 2002-03-12 2010-02-04 Bristol Myers Squibb Co C3-cyanoepothilonderivate
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
US6900208B2 (en) 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
JP2006514681A (ja) 2002-05-20 2006-05-11 コーザン バイオサイエンシス インコーポレイテッド エポチロンｄの投与方法
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
TW200401638A (en) 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
DE10232094A1 (de) 2002-07-15 2004-02-05 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 5-Thiaepothilone und 15-disubstituierte Epothilone
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
IL166039A0 (en) 2002-07-31 2006-01-15 Schering Ag New effector conjugates process for their production and their pharmaceutical use
CN100439374C (zh) 2002-08-02 2008-12-03 诺瓦提斯公司 埃坡霉素衍生物
WO2004013145A1 (en) 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2004016269A1 (en) 2002-08-17 2004-02-26 The Queens Universlty Of Belfast Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
WO2004018635A2 (en) 2002-08-21 2004-03-04 Kosan Biosciences, Inc. Myxococcus xanthus bacteriophage mx9 transformation and integration system
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
JP2006508912A (ja) 2002-08-23 2006-03-16 メディゲーネ オンコロギー ゲゼルシャフト ミット ベシュレンクテル ハフツング 非小胞性カチオン脂質調製物
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1534710B1 (en) 2002-09-04 2007-10-24 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
ATE362474T1 (de) 2002-09-04 2007-06-15 Schering Corp Pyrazolo(1,5-a)pyrimidine als hemmstoffe cyclin- abhängiger kinasen
US20040043089A1 (en) 2002-09-04 2004-03-04 Rabie A-Bakr M Buguzhi agent and composition and methods of preparing and administering the same
ATE364608T1 (de) 2002-09-04 2007-07-15 Schering Corp Pyrazolopyrimidine als hemmstoffe cyclin- abhängiger kinasen
TW200412966A (en) 2002-09-04 2004-08-01 Schering Corp Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0221312D0 (en) 2002-09-13 2002-10-23 Novartis Ag Organic compounds
US20040115319A1 (en) 2002-09-16 2004-06-17 Agcert International, Llc Food-borne pathogen and spoilage detection device and method
ES2297203T3 (es) 2002-09-19 2008-05-01 Schering Corporation Pirazolopiridinas como inhibidores de quinasas dependientes de ciclina.
AR041291A1 (es) 2002-09-19 2005-05-11 Schering Corp Imidazopiridinas como inhibidores de quinasa dependientes de ciclina
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
MY134589A (en) 2002-09-23 2007-12-31 Schering Corp Imidazopyrazines as cyclin dependent kinase inhibitors
EP1542998A4 (en) 2002-09-23 2007-01-31 Bristol Myers Squibb Co PROCESS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILON B, AND RINSE CRYSTAL STRUCTURES OF EPOTHILON B
MXPA05003119A (es) 2002-09-23 2005-06-22 Schering Corp Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas.
US20040058899A1 (en) 2002-09-25 2004-03-25 Klimko Peter G. Use of epothilones and analogs in conjunction with ophthalmic surgery
EP1545529A4 (en) 2002-09-30 2010-03-03 Bristol Myers Squibb Co NEW TYROSINE KINASE HEMMER
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
US7091193B2 (en) 2002-10-09 2006-08-15 Kosan Biosciences Incorporated Therapeutic formulations
BR0315169A (pt) 2002-10-09 2005-08-23 Kosan Biosciences Inc Referência cruzada a pedidos de patente relacionados
AU2003264822A1 (en) 2002-10-11 2004-05-04 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
CA2501717C (en) 2002-10-15 2012-09-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of epothilone derivatives for the treatment of hyperparathyroidism
AU2003287526A1 (en) 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
EP2135867B1 (en) 2002-11-07 2013-09-25 Kosan Biosciences Incorporated Trans-9, 10-dehydroepothilone C and trans-9, 10-dehydroepothilone D, analogs thereof and methods of making the same
US7001922B2 (en) 2002-11-14 2006-02-21 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs
US7645782B2 (en) 2002-11-28 2010-01-12 Wolfgang Richter Thia-epothilone derivatives for the treatment of cancer
US8088605B2 (en) 2002-12-04 2012-01-03 Technologies Biolactics Inc. Exopolysaccharides delivery system for active molecules
DE10256982A1 (de) 2002-12-05 2004-06-24 Schering Ag Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung
EP1581218A1 (en) 2002-12-05 2005-10-05 Schering AG Epothilone analogs for site specific delivery in the treatment of proliferative diseases
US20040172127A1 (en) 2002-12-09 2004-09-02 John Kantor Modular stent having polymer bridges at modular unit contact sites
WO2004052361A1 (en) 2002-12-09 2004-06-24 Novartis Ag Microtubule stabilisers for treating stenosis in stents
MXPA05006169A (es) 2002-12-09 2006-03-30 American Biosciences Composiciones y metodos para el suministro de agentes farmacologicos.
AU2003303058A1 (en) 2002-12-12 2004-07-09 Conforma Therapeutics Corporation Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
CA2508831C (en) 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
GB0230024D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
EP1581539A4 (en) 2003-01-03 2007-09-19 Bristol Myers Squibb Co NEW TYROSINE KINASE HEMMER
AU2003219947A1 (en) 2003-02-26 2004-09-28 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
GB0305928D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
GB0306907D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
US20050002983A1 (en) 2003-03-28 2005-01-06 Johnson Robert G. Devices, methods, and compositions to prevent restenosis

Also Published As

Publication number Publication date
JP2011195589A (ja) 2011-10-06
DE60330407D1 (de) 2010-01-14
IL167046A (en) 2012-06-28
EP1506203B1 (en) 2007-01-03
AU2003260002A1 (en) 2004-03-11
NZ538522A (en) 2008-03-28
EP1767535A1 (en) 2007-03-28
PT1506203E (pt) 2007-04-30
DE60310916T2 (de) 2007-11-15
ES2336937T3 (es) 2010-04-19
PT1767535E (pt) 2010-02-24
WO2004018478A2 (en) 2004-03-04
WO2004018478A3 (en) 2004-12-09
US20090149516A1 (en) 2009-06-11
PH12012501351A1 (en) 2014-10-13
DE60310916D1 (de) 2007-02-15
ES2281692T3 (es) 2007-10-01
ATE450534T1 (de) 2009-12-15
KR101173510B1 (ko) 2012-08-21
CA2496477C (en) 2012-10-16
EP2186811A1 (en) 2010-05-19
KR20050083652A (ko) 2005-08-26
JP4791183B2 (ja) 2011-10-12
EP1506203A2 (en) 2005-02-16
DK1506203T3 (da) 2007-05-14
DK1767535T3 (da) 2010-04-12
MXPA05002113A (es) 2005-06-03
ATE350383T1 (de) 2007-01-15
US7875638B2 (en) 2011-01-25
JP2006502246A (ja) 2006-01-19
CN102532120A (zh) 2012-07-04
AU2003260002B2 (en) 2010-03-18
CA2496477A1 (en) 2004-03-04
EP1767535B1 (en) 2009-12-02
CN1759115A (zh) 2006-04-12

Similar Documents

Publication Publication Date Title
SI1767535T1 (sl) Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh
WO2003059898A3 (en) Eponemycin and epoxomicin analogs and uses thereof
MXPA04004548A (es) Acidos heteroarilalalcanoicos substituidos y su uso como inhibidores de aldosa reductasa.
YU65802A (sh) Derivati azetidina, njihovo dobivanje i farmaceutske smeše koje ih sadrže
MY141521A (en) 5-substituted-six-membered heteroaromatic glucokinase activators
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
IL176062A0 (en) Dpp-iv inhibitors
AU2003228770A8 (en) Substituted pyrazolopyrimidines
PL1696905T3 (pl) Zastosowanie podstawionych 2-aminotetralin do zapobiegawczego leczenia choroby parkinsona
MXPA05012837A (es) Inhibidores de caspasa y usos de los mismos.
WO2003022844A3 (en) Synthesis of epothilones intermediates thereto and analogues thereof
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
AU2003300385A8 (en) Anticancer compounds
WO2005084222A3 (en) Synthesis of epothilones, intermediates thereto, analogues and uses thereof
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
DE60201074D1 (en) Pyrazolopyridinderivate
MXPA06003345A (es) Derivados de aminopiridina como inhibidores de la no-sintasa inducible.
WO2003080631A3 (en) Plasma carboxypeptidase b inhibitors
EP1253139A3 (en) Multioligoanilinated fullerenes
IL173895A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
DE60213541D1 (de) Discodermolid-Analoga und ihre pharmazeutische Verwendung
TW200508208A (en) Novel compound of 6-methyl-3-phenethyl-3,4-dihydro-1H-quinazoline-2-thione, its preparation and a depigmentation composition containing the same as an effective component
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
TW200603801A (en) Novel dialkoxy-imidazopyridines